OU researcher receives Cancer Foundation Fellowship for imaging breakthrough
Grant and Award Announcement
Updates every hour. Last Updated: 10-May-2025 11:09 ET (10-May-2025 15:09 GMT/UTC)
The paper, titled, Expanding the human gut microbiome atlas of Africa, was published today in Nature, the world’s leading scientific journal.
The gut microbiome has a significant impact on human health, and the lack of knowledge of the diversity of microbiomes in Africa has been a barrier to future health interventions and research.
The study is a critical development in gut health research globally as much more can now be learned, particularly about diseases such as cancer, diabetes, and obesity, and their relationship to gut microbiota.
A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy. Exploratory analysis suggests greater HER2 amplification in a tumor may be associated with greater clinical benefit of dual HER2 inhibitor vs EGFR inhibitor therapy.
Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective approach to developing novel targeted therapies for cancer and other chronic diseases. The MYC family of proteins, which are transcription factors, play a pivotal role in many cellular processes. However, dysregulation of MYC, such as amplification of MYCN, is associated with tumorigenesis, especially for neuroblastoma. MDM2, on the other hand, is one of the most frequently studied oncogenes and is an excellent target for cancer therapy, based on its p53-dependent and p53-independent oncogenic activities in various cancers.
A team led by the Cancer Immunogenomics group at the Josep Carreras Leukaemia Research Institute, the Computational Biology group at the Barcelona Supercomputing Center and the Germans Trias i Pujol Research Institute shows, for the first time, that within a tumour, the expression of the different hallmarks of cancer is not cell-specific, but rather position-specific. Under this new light, tumour architecture emerges as a valuable source of information to understand tumour dynamics and predict its sensitivity to anticancer drugs.
In a recent study, researchers demonstrated that Z526, a novel dithiocarbamate-like compound, mitigates cancer-associated cachexia (CAC) both in vitro and in vivo. Oral administration of Z526 slowed weight loss and improved muscle atrophy, fat loss, and grip force. Furthermore, the authors elucidated that Z526 potentiates anti-CAC effects by regulating NF-κB signaling and suppressing oxidative stress.
Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the available evidence, published in the open access journal Regional Anesthesia & Pain Medicine. Notwithstanding wide regional variations, platinum based drugs, taxanes, and lung cancer seem to be associated with the highest rates of persistent painful neuropathy, lasting at least 3 months, the findings suggest, prompting the researchers to call for tailored approaches to pain relief.